Gastric cancer: p-mTOR a more valuable prognostic marker than mTOR
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
In gastric cancer (GC) phosphorylated mammalian target of rapamycin (p-mTOR) is a more valuable prognostic marker than mTOR.
Why this matters
Novel prognostic biomarker for GC urgently needed.
mTOR, p-mTOR, p70S6k, and p-p70S6K expression rates were 60.8%, 54.2%, 53.3%, and 53.3%, respectively.
mTOR and p70S6K overexpression were not significantly associated with clinical variables.
p-mTOR expression was significantly associated with differentiation (P<.01), depth of invasion (P<.01), lymph node metastasis (P=.04) and TNM stage (P=.02); p-p70S6K was associated with differentiation (P=.006), invasion depth (P<.001), and TNM stage (P=.02).
Differentiation, invasion depth, lymph node metastasis, and TNM stage were not related to OS (all P.05); p-mTOR and p-p70S6K expression were closely associated with OS (P=.006 and P<.001, respectively), but mTOR and p70S6K were not.
Meta-analysis revealed no relationship between mTOR overexpression and any clinicopathological variables; p-mTOR was correlated with depth of invasion and TNM stage (both P<.05), and overexpression associated with shorter survival (P<.001).